Company Overview
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Why Investors Should Care
Revenue has grown at a 32.0% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $170.44M (+104.5% YoY); net profit $-193.88M.
- Trailing 12 Months Year-on-year growth — revenue -92.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 32.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 32.01% |
| 1 Year: | -92.80% |
Stock Price Performance
| 1 Year: | +41.26% |
| 6 Months: | -15.76% |
| 3 Months: | +35.95% |
| 1 Month: | +95.70% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.92 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 32.0% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RGNX REGENXBIO Inc. R2K | 12.29 | -2.19 | $635.36M | 0.00% | -48.13% | - | 32.01% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 455.00K | 6.56M | 1.34M | 2.04M | 132.39M | 40.03M | 5.31M | 40.78M | 884.00K | 7.88M | 14.70M | 11.77M | 17.64M | 16.57M | 98.91M | 21.45M | 18.88M | 22.04M | 30.77M | 22.22M | 32.65M | 26.51M | 19.14M | 19.98M | 28.91M | 15.62M | 22.30M | 24.20M | 89.01M | 21.36M | 29.73M | 6.39M |
| Operating Income | -3.99M | -6.30M | -7.35M | - | -11.25M | -14.95M | -18.67M | - | -22.92M | -15.06M | -21.31M | - | 102.03M | 6.35M | -22.73M | - | -35.91M | -36.87M | -35.90M | - | -37.70M | -41.83M | 13.95M | - | -44.04M | -52.23M | -57.35M | -71.53M | -62.53M | -71.05M | -66.16M | -73.11M | -64.96M | -63.86M | -56.04M | -62.08M | 12.13M | -63.28M | -52.41M | -83.36M |
| Net Income | -4.01M | -6.29M | -7.33M | -5.18M | -10.77M | -14.44M | -18.15M | -19.61M | -21.99M | -14.47M | -20.71M | -16.00M | 104.24M | 10.59M | -19.20M | 4.31M | -32.23M | -1.46M | -34.58M | -26.46M | -40.04M | -33.76M | 8.79M | -46.24M | -50.14M | -57.64M | -58.41M | -76.72M | -68.18M | -75.48M | -66.68M | -72.06M | -61.87M | -63.33M | -52.99M | -59.60M | 6.08M | -70.87M | -61.94M | -90.05M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.82 | -0.47 | -0.67 | -0.51 | 3.04 | 0.30 | -0.56 | 0.11 | -0.89 | -0.04 | -0.94 | -0.72 | -1.08 | -0.91 | 0.23 | -1.24 | - | -1.36 | -1.37 | -1.79 | -1.58 | -1.75 | -1.53 | -1.66 | -1.41 | -1.38 | -1.05 | -1.17 | 0.12 | -1.38 | -1.20 | -1.72 |
| R&D Expense | 2.79M | 4.01M | 5.66M | 4.81M | 6.18M | 10.68M | 12.56M | 16.06M | 16.62M | 13.92M | 12.52M | 14.17M | 19.55M | 21.49M | 18.51M | 24.33M | 25.20M | 29.48M | 35.69M | 33.81M | 37.03M | 38.11M | 43.97M | 47.18M | 39.72M | 45.88M | 47.85M | 55.63M | 61.01M | 63.31M | 58.52M | 59.89M | 58.18M | 54.84M | 48.87M | 54.43M | 53.09M | 59.50M | 56.10M | 57.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.09M | 6.12M | 7.59M | 4.59M | 10.39M | 218.50M | 35.23M | 154.57M | 470.35M | 112.72M | 90.24M | 83.33M | 170.44M |
| Operating Income | -4.78M | -3.68M | -23.14M | -65.34M | -75.89M | 88.10M | -149.00M | -119.23M | 159.98M | -262.88M | -268.13M | -233.35M | -161.20M |
| Net Income | -5.39M | -4.00M | -22.81M | -62.97M | -73.17M | 99.94M | -94.73M | -111.25M | 127.84M | -280.32M | -263.49M | -227.10M | -193.88M |
| Diluted EPS | - | - | - | -2.38 | -2.45 | 2.73 | -2.58 | -2.98 | 2.91 | -6.50 | -6.02 | -4.59 | -3.76 |
| R&D Expense | 5.05M | 4.96M | 17.28M | 45.48M | 57.22M | 83.87M | 124.19M | 166.29M | 181.44M | 242.45M | 232.27M | 208.52M | 228.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 3.49M | 221.38M | 172.73M | 198.68M | 543.81M | 497.91M | 708.16M | 1.11B | 833.27M | 573.97M | 465.99M | 453.03M |
| Total Equity | -8.11M | -13.92M | -18.29M | 216.81M | 161.74M | 183.03M | 508.85M | 450.20M | 377.75M | 764.30M | 516.20M | 311.74M | 259.65M | 102.73M |
| Cash & Equivalents | 2.17M | 1.12M | 1.12M | 54.12M | 24.84M | 46.66M | 75.56M | 69.51M | 338.43M | 345.21M | 96.95M | 34.52M | 57.53M | 34.47M |
| Total Liabilities | - | - | 9.19M | 4.57M | 10.99M | 15.65M | 34.97M | 47.71M | 330.41M | 349.61M | 317.07M | 262.23M | 206.34M | 350.30M |
| Current Liabilities | - | - | 9.19M | 4.34M | 9.67M | 14.44M | 22.18M | 33.68M | 81.45M | 130.47M | 130.43M | 130.27M | 103.19M | 118.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -48.56M | -57.99M | 104.65M | -107.70M | -54.06M | 218.88M | -207.49M | -218.41M | -173.12M | -123.96M |
| Investing Cash Flow | - | 19.39M | -4.79M | -279.36M | 93.56M | 122.76M | -406.64M | -11.93M | 190.94M | 103.45M | -15.87M |
| Financing Cash Flow | - | 119.00K | 84.60M | 204.44M | 8.38M | 200.21M | 195.25M | -28.84M | -34.97M | 92.68M | 116.77M |
| Capital Expenditure | -522.00K | -8.15M | -7.16M | -13.28M | -11.72M | -26.87M | -84.17M | -30.72M | -9.96M | -2.44M | -2.41M |
| Free Cash Flow | - | -56.71M | -65.15M | 91.37M | -119.42M | -80.93M | 134.70M | -238.21M | -228.37M | -175.56M | -126.38M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -78.5% | -60.2% | -304.9% | -1,423.8% | -730.2% | 40.3% | -422.9% | -77.1% | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% |
| Net Margin % | -88.5% | -65.4% | -300.6% | -1,372.1% | -704.0% | 45.7% | -268.9% | -72.0% | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% |
| ROE % | 38.7% | 21.9% | -10.5% | -38.9% | -40.0% | 19.6% | -21.0% | -29.5% | 16.7% | -54.3% | -84.5% | -87.5% | -188.7% |
| ROCE % | - | 64.6% | -10.7% | -40.1% | -41.2% | 16.9% | -32.1% | -19.0% | 16.3% | -37.4% | -60.4% | -64.3% | -48.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 11.19% | 5.78M | $87.61M |
| 2 | Redmile Group, LLC | 8.45% | 4.37M | $66.19M |
| 3 | JPMORGAN CHASE & CO | 6.74% | 3.48M | $52.78M |
| 4 | State Street Corporation | 5.28% | 2.73M | $41.38M |
| 5 | Morgan Stanley | 4.00% | 2.07M | $31.30M |
| 6 | Vanguard Capital Management LLC | 3.88% | 2.01M | $30.41M |
| 7 | Goldman Sachs Group Inc | 3.56% | 1.84M | $27.87M |
| 8 | Integral Health Asset Management, LLC | 2.90% | 1.50M | $22.72M |
| 9 | Qube Research & Technologies Ltd | 2.53% | 1.31M | $19.85M |
| 10 | Geode Capital Management, LLC | 2.20% | 1.14M | $17.23M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RGNX
RGNX Stock Dips As Traders Weigh Heavy Losses And Cash Runway - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE1ScTkzQlVxMjRUWGo0YXZJajVCQk43VDRiakdMWjl0WHBMQVBYX1V1S1poMDFiM01SbFIzajBYaWRsaUUxTGlYeWF6bFZjSFl4THpNLUcwTW1XbWk1OUYzTGZuWmczOGJFaWI2X2xaMk43b2M?oc=5" target="_blank">RGNX Stock D…
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQX2c4M0RLM2NtTnBJM1AzRGdMOUROUkR4SURJbW96YjVESTlLVWNYV3VHNTRXUmFjc3hfMXNUSkhIU2hyYkJkb3QwYzFrWWdaaGhrSi1nZV9paEFRSFpURS1udEQ0THlESkpvakw4RXN4X2pxTzMxRHpPTldEQkFQaVBvSWNyVmkzMkFVc2…
REGENXBIO doses first patient in eye-disease gene therapy trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNM1Z4dUh0U1R1MmNaYW9zd3VlVWF6QjVQb3BsVGVzMG1wa19UTTBISk9LaU4ycE5halJsZ011WTE2dmQ2LWtyQkpweXpKOWpMYzZkeUFvVVRnSlA2TDRnT19hajJsZnplaUh3eUFxcHlNZWY5RmIxQWFKeWp2ZklucEdmdjczanVlSGVtRm…
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRWVvVXg1Zld5QUt6TlpMZ3pxb0ZXOFRPcWhoRGZHVEJMZHo2QTFXVU96OWVCTU1qNnlnemFHbUt2V1FSQjJRc0tlQUdaMTQyMTNOeDNUcnh6b1J6VFpDQWkybVhKY1JIVkZNZ3F5bURKUENFcjJQRE9NblQ0RWx5RlhaamNiQTZydHZIQz…
RGNX Stock On Track For Worst Day Ever As Big Q1 Loss, Cash Concerns Eclipse Duchenne Trial Success - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxOMUZBWUp1TzVJa0hoQjhoaTNRTnUtVFNEM05tYUVjNDV1WXZZX09JZ21WTEt6N0pKRFhMaXFLRTVJVVVNRG12Q2NTSkl3ekxMbnFrVmJ1RDJqeVJQX1dfVGhoVzBsVXBTZzRYTGlFTFM3ZUh5Mzd5VmY5dDRmclFpd29HZ0Y4d0ppQWJ0QU…
(RGNX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQSm8zSThNU29jZkMxRHNRaUpiV0lvTHUzbE5RU2xfSVZucFJ5MGNWRFF2RnBfUzFhSVMzMi0xbFo4cXlmaUdZUlYzUm43blY4eWRJbVhKTVhrMWxnRHNTSE1IOUZyNklDZ3lDY2FBN1liX0h4X3I5YU5oZ05SN29IMUkzbno0QVhzSVdzZ3…
RGNX — Frequently Asked Questions
What is the current share price of REGENXBIO Inc. (RGNX)?
As of 2026-07-14 21:23 PDT, REGENXBIO Inc. (RGNX) trades at $12.29 on NasdaqGS. Its 52-week range is $5.65 to $15.98.
What is the market capitalisation of RGNX?
REGENXBIO Inc. (RGNX) has a market capitalisation of $635.36M on NasdaqGS.
What is the P/E ratio of RGNX?
RGNX trades at a trailing price-to-earnings (P/E) ratio of -2.19. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 16.32.
Is RGNX a good stock to buy?
This page provides a data-driven analysis of REGENXBIO Inc. (RGNX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.